Imatinib

Chemical formula: C₂₉H₃₁N₇O  Molecular mass: 493.603 g/mol  PubChem compound: 5291

Therapeutic indications

Imatinib is indicated for:

Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)

Population group: only adults (18 years old or older)

Imatinib is indicated for the treatment of:

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • adult patients with relapsed or refractory Ph+ ALL as monotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic myeloid leukaemia (CML) Philadelphia chromosome (bcr-abl) positive (Ph+)

Population group: only adults (18 years old or older)

Imatinib is indicated for the treatment of:

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
  • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Metastatic malignant gastrointestinal stromal tumours (GIST) with Kit (CD 117) positive

Population group: only adults (18 years old or older)

Imatinib is indicated for:

  • the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
  • the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Myelodysplastic/myeloproliferative diseases (MDS/MPD) with platelet-derived growth factor receptor (PDGFR) gene re-arrangements

Population group: only adults (18 years old or older)

Imatinib is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement

Population group: only adults (18 years old or older)

Imatinib is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Dermatofibrosarcoma protuberans (DFSP)

Population group: only adults (18 years old or older)

Imatinib is indicated for the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic myeloid leukaemia (CML) Philadelphia chromosome (bcr-abl) positive (Ph+)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Imatinib is indicated for the treatment of:

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
  • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Imatinib is indicated for the treatment of:

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • adult patients with relapsed or refractory Ph+ ALL as monotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: GLEEVEC Film coated tablet
Summary of Product Characteristics (SPC) 2019: GILVEC Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈